Conditions: Schizophrenia Schizoaffective Disorder
Keywords: Lurasidone Schizophrenia Latuda
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 244
Healthy volunteers: no

Brief summary:
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia. Switching between antipsychotic medications is common in the treatment of schizophrenia. The current study is designed to evaluate the effectiveness, safety, and tolerability of switching clinically stable, but symptomatic outpatients with schizophrenia or schizoaffective disorder from their preswitch antipsychotic medication to lurasidone, over a period of 6 weeks.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Lurasidone HCl
Intervention descriptions: intervention 1: Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks

Protocol document: